We’re back at it! More news on the NB front.
Here’s this week’s links…
Kids – Why We Fight
We were crushed to hear seven-year-old Jamie Inglis died this week. Jamie was diagnosed at three years old, and beat neuroblastoma once. He was in remission for 18 months before relapsing. He was undergoing treatment for his relapse in Germany when he died. His mother, Vicky Inglis, took to Jamie’s Facebook page to announce Jamie’s passing. She describes her son as an “amazing child” and says that “neuroblastoma only seeks out the best. The best is what Jamie is.” dailymail.co.uk.
Non-Profits / Events / News
Currently, one of the first treatment options for children is removal or resection of the primary tumor. However, a study by Oncology Nurse Advisor has concluded that “aggressive surgery isn’t justified for these patients”. According to their study, the invasive surgery is not likely to prolong the child’s life. news.gather.com/.
Does that title sound like a bunch of medical mumbo jumbo to you? (Because it did to me.) But what it boils down to is Paladin Labs Inc has announced that is now has an exclusive licensing agreement for a new, antibody-based immunotherapy for children with high-risk NB. The drug used in the trial, APN311, “has shown promise in improving survival rates in the treatment of children diagnosed with neuroblastoma”, according to the President and CEO or Paladin Labs Inc. The treatment is now being tested in Canada and Sub Saharan Africa. marketwire.com.
The neuroblastoma program at Texas Children’s Hospital is working towards a better understanding of the way NB tumors develop resistance to therapies. They are hoping that further understanding this relationship will provide new and improved treatment options for children with the disease. texaschildrensblog.org.
You can sign up to receive these weekly articles in your email. Sign up below…
Mind if we hang out
in your inbox?
We only email once or twice a month, always relevant to how we're working to beat neuroblastoma and other childhood cancers.
Thank you for subscribing!
Something went wrong.